双歧杆菌乳杆菌三联活菌片辅助护肝药物治疗肝硬化合并自发性腹膜炎患者的效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (40 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the effect of Bifidobacterium Lactobacillus Triple Viable Bacteria Tablets in the treatment of cirrhotic patients with spontaneous peritonitis.Methods From July 2016 to November 2017,a total of 100 patients with cirrhosis complicated with spontaneous peritonitis were selected as objects and randomly divided into observation group and control group,with 50 cases in each group.The patients in the control group were treated with conventional hepatoprotective drugs,while patients in the observation group were treated with Bifidobacterium Lactobacillus Triple Viable Bacteria Tablets on the basis of the control group.The clinical efficacy,clinical symptom remission time,immune function before and after treatment,and the recurrence rate of spontaneous peritonitis half a year follow-up after treatment of the two groups were observed.Results The total effective rate of the observation group was significantly higher than that of the control group,and the difference was statistically significant(P＜0.05).The remission time of hyperthermia,abdominal pressure pain,and rebound pain in the observation group were significantly shorter than those in the control group,and the differences were statistically significant(P＜0.05).The ratio of CD4+/CD8+T-lymphocyte subsets after treatment in the observation group was higher than that before treatment,and the difference was statistically significant(P＜0.05).The ratio of CD4+/CD8+of T-lymphocyte subsets after treatment in the observation group was significantly higher than that in the control group,and the difference was statistically significant(P＜0.05).The recurrence rate of spontaneous peritonitis after half a year follow-up in the observation group(22.0%)was significantly lower than that in the control group (46.0%),and the difference was statistically significant(P＜0.05).Conclusion Bifidobacterium Lactobacillus Triple Viable Bacteria Tablets are effective in the clinical treatment of patients with cirrhosis and spontaneous peritonitis,which can effectively relieve the clinical symptoms and improve the immune function of patients with liver cirrhosis and spontaneous peritonitis,thereby reducing the recurrence rate,and they are worthy of clinical promotion and application.

Key words： Bifidobacterium Lactobacillus Triple Viable Bacteria Tablets Liver protection drugs Liver cirrhosis Spontaneous peritonitis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIN Ren-ping

Cite this article:

LIN Ren-ping. Effect of Bifidobacterium Lactobacillus Triple Viable Bacteria Tablets on liver protection in patients with cirrhosis complicated with spontaneous peritonitis[J]. 中国当代医药, 2018, 25(21): 95-97转101.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I21/95

[1]	陈于兰，陈于祥，杨勇，等.肝硬化合并自发性腹膜炎的治疗分析[J].局解手术学杂志，2014，20（5）：518-519.
[2]	谢和平，杨宏志，关卫兵，等.肝硬化合并自发性腹膜炎的中医学病证研究[J].中国中西医结合急救杂志，2015，14（3）：131-134.
[3]	骆成林，呼闯营，殷国建，等.产ESBLs细菌在肝硬化合并自发性腹膜炎患者腹水中的检测及其耐药性[J].世界华人消化杂志，2016，17（15）：1567-1569.
[4]	陈俊，严正平，王笑秋，等.肝硬化合并自发性腹膜炎患者的危险因素分析[J].山东医药，2015，48（38）：79-80.
[5]	徐佳，温晓玉.非选择性β受体阻滞剂增加肝肾综合征的风险和肝硬化合并自发性腹膜炎患者的病死率[J].临床肝胆病杂志，2014，34（7）：677-678.
[6]	邵东，汪良芝.肝硬化合并自发性腹膜炎腹水细胞因子测定的临床意义[J].实用临床医药杂志，2015，13（7）：84-86.
[7]	姚朝光.哌拉西林/他唑巴坦治疗肝硬化合并自发性腹膜炎的临床观察[J].中华医院感染学杂志，2013，23（3）：657-659.
[8]	张颖，张志广.肝硬化合并自发性腹膜炎患者降钙素原和C反应蛋白检测的临床意义[J].临床荟萃，2016，25（8）：665-668.
[9]	艾黎明，徐兆军，胡长娥，等.腹腔灌洗后局部应用抗生素治疗肝硬化合并自发性腹膜炎72例临床观察[J].传染病信息，2015，20（1）：53.
[10]	程宁，林海燕，邓琳，等.一次性放腹水联合局部应用抗菌素治疗肝硬化合并自发性腹膜炎的临床研究[J].中外健康文摘，2012，34（42）：116-117.
[11]	陈林，周祖模，石勇明，等.肝硬化合并自发性腹膜炎优势菌及耐药分析[J].国际流行病学传染病学杂志，2015，37（4）：241-243.
[12]	Gaiani S，Gramantieri L，Venturoli N.What is the criterion of differentiating chronic hepatitis from compen sated cirrhosis？A prospective study comparing ultrasonography and percutaneous liver biopsy[J].J Hepatol，2016，27（6）：979-985.
[13]	Ji DC，Himyasu I，Hiroko I.Expression of cyelooxygenase-2 and cytosolic phospholipase A2 in the liver tissue of patients with chronic hepatitis and liver cirrhosis[J].Hepatol Res，2015，23（13）：185-195.
[14]	Wang JH，Lu SN，Lee CM.Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis[J].Scand J Gastroenterol，2016，37（52）：366-369.
[15]	Onodera K，Kato A，Suzuki K.Serum leptin concentrations in liver cirrhosis：relationship to the severity of liver dysfunction and their characteristic diurnal profiles[J].Hepatol Res，2015，21（12）：205-212.